New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol
CONCLUSIONS: Cannabidiol is positioned as an innovative therapy that allows better control of epileptic seizures and comorbidities of DS and LGS, furthermore its efficacy and safety have been evaluated in more than 700 patients. In CTs, cannabidiol significantly reduced the percentage of convulsive seizures and drop seizures compared to placebo in patients with DS and LGS respectively, which could improve their quality of life and that of their family members. The most frequent adverse effects reported were somnolence and decreased appetite. Elevated liver aminotransferase levels were also reported, especially in patients given concomitant sodium valproate. This therapy may allow better control of the epileptic seizures associated with these syndromes.PMID:33908026 | DOI:10.33588/rn.72S01.2021017
Authors: Kim JS, Hong SH, Kim WS PMID: 33029988 [PubMed]
CONCLUSIONS: In addition to bilateral HA, CNS infection alone was not a poor prognostic factor for the CNS infection-related epilepsy with HA group compared with the conventional MTLE with HA group. Based on these negative results, HA is a plausible and relevant lesion with similar clinical characteristics to HA in patients with conventional MTLE. Therefore, CNS infection-related MTLE with isolated HA might represent another subtype of MTLE with HA with a different etiology. PMID: 33029977 [PubMed]
Authors: Kim EH, Shim WH, Lee JS, Yoon HM, Ko TS, Yum MS Abstract BACKGROUND AND PURPOSE: Recent quantitative neuroimaging studies of childhood absence epilepsy (CAE) have identified various structural abnormalities that might be involved in the onset of absence seizure and associated cognitive and behavioral functions. However, the neuroanatomical alterations specific to CAE remain unclear, and so this study investigated the regional alterations of brain structures associated with newly diagnosed CAE. METHODS: Surface and volumetric magnetic resonance imaging data of patients with newly diagnosed CAE (n=18) an...
Authors: Seo JG, Cho YW, Kim KT, Kim DW, Yang KI, Lee ST, Byun JI, No YJ, Kang KW, Kim D, Drug Committee of Korean Epilepsy Society Abstract The incidence and prevalence of epilepsy are highest in elderly people, and the etiologies of epilepsy in the elderly differ from those in other age groups. Moreover, diagnosing and treating epilepsy in elderly people may be challenging due to differences in clinical characteristics and physiological changes associated with aging. This review focuses on the pharmacological treatment of epilepsy in elderly patients. PMID: 33029960 [PubMed]
Authors: Kim H, Kim DW, Lee ST, Byun JI, Seo JG, No YJ, Kang KW, Kim D, Kim KT, Cho YW, Yang KI, Drug Committee of Korean Epilepsy Society Abstract Epilepsy is a common neurological disorder that is mainly treated using antiepileptic drugs. Several antiepileptic drugs such as phenobarbital, phenytoin, primidone, and ethosuximide were developed in the early 20th century. More than 10 types of antiepileptic drugs have been developed since the 1990s, and there are now more than 20 antiepileptic drugs in active clinical use. The choice of antiepileptic drugs is based on the clinical features of the seizure types, elect...
Authors: Jang Y, Kim DW, Yang KI, Byun JI, Seo JG, No YJ, Kang KW, Kim D, Kim KT, Cho YW, Lee ST, Drug Committee of Korean Epilepsy Society Abstract Autoimmune epilepsy is a newly emerging area of epilepsy. The concept of "autoimmune" as an etiology has recently been revisited thanks to advances in autoimmune encephalitis and precision medicine with immunotherapies. Autoimmune epilepsy presents with specific clinical manifestations, and various diagnostic approaches including cerebrospinal fluid analysis, neuroimaging, and autoantibody tests are essential for its differential diagnosis. The diagnosis is o...
Publication date: Available online 9 October 2020Source: Epilepsy &BehaviorAuthor(s): Fabrizio Bert, Erika Pompili, Maria Rosaria Gualano, Silvio Venuti, Davide Minniti, Roberta Siliquini
Publication date: Available online 8 October 2020Source: SeizureAuthor(s): André Peres Gama, Mariângela Taura, Neide Barreira Alonso, Artur Menezes Sousa, Maria Helena da Silva Noffs, Elza Márcia Yacubian, Laura Maria Guilhoto
Since its first reported use in humans in 1988 and more than 100,000 subsequent implantations, VNS has generated growing interest in the management of drug-resistant epilepsy (DRE) . These represent around 30% of all epilepsy cases . The average prevalence of epilepsy in the world is estimated at around 7.60 cases/1,000 inhabitants, with an average annual incidence of 67.77 cases/100,000 inhabitants . The functional prognosis and survival associated with this condition are influenced by major trauma and psychiatric and cognitive comorbidities.
It would dedicate $1.5 billion of its total to research and therapy for Alzheimer ’s Disease, Parkinson’s Disease, stroke, epilepsy and other brain and central nervous system conditions.